A Head-to-Head Comparison of the Validity and Predictive Ability of Diagnosis Versus Medication-Based Comorbidity Indices

Author(s)

Platen M1, Buchholz M2, Rädke A2, Hoffmann W3, Michalowsky B2
1German Center for Neurodegenerative Diseases (DZNE), Bonn, NW, Germany, 2German Center for Neurodegenerative Diseases (DZNE), Greifswald, MV, Germany, 3Institute for Community Medicine, University Medicine Greifswald, Greifswald, MV, Germany

OBJECTIVES: To compare the performance of the diagnosis-based Charlson comorbidity index (CCI) and medication-based Rx-Risk comorbidity index (Rx-Risk).

METHODS: This analysis used data from n=221 patients from the InDePendent Study. CCI and Rx-Risk scores were calculated using documented ICD-10 diagnoses and prescribed medications from general practitioner practices. Health-related quality of life (HRQoL, EQ-5D-5L), functional impairment (B-ADL), cognitive decline (MMSE), and healthcare utilization (physician visits, hospitalizations) were assessed via interviews. Indices performance was evaluated in terms of agreement (Cohens Kappa (k)), known-group validity (ANOVA, t-test), convergent validity (correlation coefficient (rs)) and predictive ability (R², Akaike information criterion (AIC)).

RESULTS: Patients averaged 80 years old, were more likely female (55%), and had, on average, 12 diagnoses and seven medications. The agreement between both indices was poor for all conditions except diabetes (k =0.645) and chronic airway diseases (k =0.486). Rx-Risk differed more than CCI in known groups, especially for HRQoL and hospitalization. Both indices yielded poor correlations. However, Rx-Risk had a better convergent validity than CCI for the EQ-5D index (rs, -0.215 vs. -0.134), and risk of hospitalization (rs, 0.145 vs. 0.128). The predictive ability of both indices was good. Rx-Risk performed better than the CCI in predicting the change of the EQ-5D index (R², 30% vs. 28%), functional (R², 55 vs. 52%) and cognitive decline (R², 46 vs. 47%), and all EQ-5D dimensions (mobility (AIC, 489.4 vs. 490.2); self-care (AIC, 552.5 vs. 557.5); usual activities (AIC, 580.6 vs. 584.4); pain/discomfort (AIC, 467.2 vs. 470.0); anxiety/depression (AIC, 446.9 vs. 447.3)) and physician consultations (AIC, 649.2 vs. 551.0), except for hospitalization (AIC, 149.2 vs. 147.1).

CONCLUSIONS: The Rx-Risk's was slightly superior in validity and predictive ability, especially regarding HRQoL and healthcare utilization. However, caution is warranted due to limitations in assessing functional and cognitive impairment, suggesting that alternative instruments should be considered to predict such outcomes better.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

MSR218

Topic

Epidemiology & Public Health, Methodological & Statistical Research, Patient-Centered Research, Real World Data & Information Systems

Topic Subcategory

Disease Classification & Coding, Health & Insurance Records Systems, Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods

Disease

Geriatrics, Mental Health (including addition), Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×